JP2024056817A5 - - Google Patents

Download PDF

Info

Publication number
JP2024056817A5
JP2024056817A5 JP2024018149A JP2024018149A JP2024056817A5 JP 2024056817 A5 JP2024056817 A5 JP 2024056817A5 JP 2024018149 A JP2024018149 A JP 2024018149A JP 2024018149 A JP2024018149 A JP 2024018149A JP 2024056817 A5 JP2024056817 A5 JP 2024056817A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024018149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024056817A (ja
Filing date
Publication date
Priority claimed from PCT/IB2022/055170 external-priority patent/WO2022254379A1/en
Application filed filed Critical
Publication of JP2024056817A publication Critical patent/JP2024056817A/ja
Publication of JP2024056817A5 publication Critical patent/JP2024056817A5/ja
Pending legal-status Critical Current

Links

JP2024018149A 2021-06-04 2024-02-08 抗sirp-アルファ抗体 Pending JP2024056817A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163197259P 2021-06-04 2021-06-04
US63/197,259 2021-06-04
US202263325828P 2022-03-31 2022-03-31
US63/325,828 2022-03-31
US202263339326P 2022-05-06 2022-05-06
US63/339,326 2022-05-06
PCT/IB2022/055170 WO2022254379A1 (en) 2021-06-04 2022-06-02 Anti-sirp-alpha antibodies
JP2022576817A JP7436711B2 (ja) 2021-06-04 2022-06-02 抗sirp-アルファ抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022576817A Division JP7436711B2 (ja) 2021-06-04 2022-06-02 抗sirp-アルファ抗体

Publications (2)

Publication Number Publication Date
JP2024056817A JP2024056817A (ja) 2024-04-23
JP2024056817A5 true JP2024056817A5 (https=) 2024-05-21

Family

ID=82156310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022576817A Active JP7436711B2 (ja) 2021-06-04 2022-06-02 抗sirp-アルファ抗体
JP2024018149A Pending JP2024056817A (ja) 2021-06-04 2024-02-08 抗sirp-アルファ抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022576817A Active JP7436711B2 (ja) 2021-06-04 2022-06-02 抗sirp-アルファ抗体

Country Status (19)

Country Link
US (2) US11572412B2 (https=)
EP (1) EP4347653A1 (https=)
JP (2) JP7436711B2 (https=)
KR (1) KR20240027677A (https=)
AU (1) AU2022284373A1 (https=)
BR (1) BR112023025194A2 (https=)
CA (1) CA3218692A1 (https=)
CL (2) CL2023003554A1 (https=)
CO (1) CO2023017156A2 (https=)
CR (1) CR20230573A (https=)
DO (1) DOP2023000259A (https=)
EC (1) ECSP23088844A (https=)
IL (1) IL308741A (https=)
JO (1) JOP20230311A1 (https=)
MX (1) MX2023014389A (https=)
PH (1) PH12023553159A1 (https=)
SA (1) SA523451800B1 (https=)
TW (1) TW202317620A (https=)
WO (1) WO2022254379A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102702926B1 (ko) * 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
TW202317620A (zh) 2021-06-04 2023-05-01 德商百靈佳殷格翰國際股份有限公司 抗SIRPα抗體
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2025072871A2 (en) * 2023-09-28 2025-04-03 Memorial Sloan-Kettering Cancer Center ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
WO2025074337A1 (en) 2023-10-06 2025-04-10 Boehringer Ingelheim International Gmbh Use of anti-sirp-alpha antibodies to treat a liver disease or disorder
WO2025074328A1 (en) 2023-10-06 2025-04-10 Boehringer Ingelheim International Gmbh Use of anti-sirp-alpha antibodies to treat cancer
JP2025154039A (ja) 2024-03-29 2025-10-10 日揮触媒化成株式会社 流動接触分解触媒及びその製造方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
HRP20150553T1 (hr) 2009-05-15 2015-08-28 University Health Network Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
CN103620032B (zh) 2010-12-31 2016-02-24 生物蛋白有限公司 抗体的快速人源化
WO2012149416A2 (en) 2011-04-28 2012-11-01 University Of Southern California Human myeloid derived suppressor cell cancer markers
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
CN105085679B (zh) 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
BR112018070823A2 (pt) 2016-04-14 2019-02-05 Ose Immunotherapeutics anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
WO2018160739A1 (en) 2017-02-28 2018-09-07 The Board Of Trustees Of The Leland Stanford Junior University Antifibrotic activity of cd47 blockade
KR102702926B1 (ko) 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
CN118271443A (zh) * 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
EP3694881A1 (en) 2017-10-13 2020-08-19 OSE Immunotherapeutics Modified anti-sirpa antibodies and uses thereof
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗sirpa抗体およびその使用法
SG11202012338QA (en) 2018-07-10 2021-01-28 Univ Kobe Nat Univ Corp ANTI-SIRPa ANTIBODY
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
JP2022507295A (ja) 2018-11-14 2022-01-18 アーチ オンコロジー,インコーポレイテッド 治療用SIRPα抗体
JP7451520B2 (ja) 2018-11-15 2024-03-18 ビョンディス・ビー.ブイ. ヒト化抗SIRPα抗体
WO2020180811A1 (en) 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
AU2020286285A1 (en) 2019-08-20 2021-03-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-SIRPa antibodies
CN111635458B (zh) 2020-03-20 2026-02-17 健信生物科技(宁波)有限公司 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
CN112010979B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 一种抗人SIRPα单克隆抗体及其用途
CN111995682B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 抗人SIRPα单克隆抗体及其用途
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
TW202317620A (zh) 2021-06-04 2023-05-01 德商百靈佳殷格翰國際股份有限公司 抗SIRPα抗體

Similar Documents

Publication Publication Date Title
JP2024056817A5 (https=)
JP2021531254A5 (https=)
JP2024109678A5 (https=)
JP2022079549A5 (https=)
RU2019118359A (ru) Антитело к cd73 человека
RU2012112829A (ru) Анти-gitr-антитела
JP2021526022A5 (https=)
IL265434B2 (en) Anti-cd27 antibodies
JP2025032102A5 (https=)
JP2023071956A5 (https=)
RU2008137531A (ru) Антитела к тимусному стромальному лимфопоэтину (tslp) и их применение
JP2022540083A5 (https=)
JP2013056885A5 (https=)
JP2020505919A5 (https=)
JP2024105229A5 (https=)
JP2022542574A5 (https=)
JP2025501775A5 (https=)
JP2023015301A5 (https=)
JP2023093753A5 (https=)
JP2022542670A5 (https=)
JP2021517459A5 (https=)
JP2023182689A5 (https=)
JP2023508674A5 (https=)
JPWO2021241616A5 (https=)
JP2022548646A5 (https=)